Cost-effectiveness of point-of-care C-Reactive Protein test compared to current clinical practice as an intervention to improve antibiotic prescription in malaria-negative patients in Afghanistan by Dickinson, Simon et al.
RESEARCH ARTICLE
Cost-effectiveness of point-of-care C-Reactive
Protein test compared to current clinical
practice as an intervention to improve
antibiotic prescription in malaria-negative
patients in Afghanistan
Simon DickinsonID
1,2*, Huey Yi Chong2, Toby Leslie1, Mark Rowland3, Kristian Schultz
HansenID
4, Dwayne Boyers2
1 Mott MacDonald Ltd, London, United Kingdom, 2 Health Economics Research Unit, University of
Aberdeen, Aberdeen, United Kingdom, 3 Department of Disease Control, London School of Hygiene and





Antimicrobial resistance (AMR) is a global health problem requiring a reduction in inappro-
priate antibiotic prescribing. Point-of-Care C-Reactive Protein (POCCRP) tests could distin-
guish between bacterial and non-bacterial causes of fever in malaria-negative patients and
thus reduce inappropriate antibiotic prescribing. However, the cost-effectiveness of
POCCRP testing is unclear in low-income settings.
Methods
A decision tree model was used to estimate cost-effectiveness of POCCRP versus current
clinical practice at primary healthcare facilities in Afghanistan. Data were analysed from
healthcare delivery and societal perspectives. Costs were reported in 2019 USD. Effective-
ness was measured as correctly treated febrile malaria-negative patient. Cost, effectiveness
and diagnostic accuracy parameters were obtained from primary data from a cost-effective-
ness study on malaria rapid diagnostic tests in Afghanistan and supplemented with
POCCRP-specific data sourced from the literature. Incremental cost-effectiveness ratios
(ICERs) reported the additional cost per additional correctly treated febrile malaria-negative
patient over a 28-day time horizon. Univariate and probabilistic sensitivity analyses exam-
ined the impact of uncertainty of parameter inputs. Scenario analysis included economic
cost of AMR per antibiotic prescription.
Results
The model predicts that POCCRP intervention would result in 137 fewer antibiotic prescrip-
tions (6%) with a 12% reduction (279 prescriptions) in inappropriate prescriptions compared
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to current clinical practice. ICERs were $14.33 (healthcare delivery), $11.40 (societal), and
$9.78 (scenario analysis) per additional correctly treated case.
Conclusions
POCCRP tests could improve antibiotic prescribing among malaria-negative patients in
Afghanistan. Cost-effectiveness depends in part on willingness to pay for reductions in inap-
propriate antibiotic prescribing that will only have modest impact on immediate clinical out-
comes but may have long-term benefits in reducing overuse of antibiotics. A reduction in the
overuse of antibiotics is needed and POCCRP tests may add to other interventions in
achieving this aim. Assessment of willingness to pay among policy makers and donors and
undertaking operational trials will help determine cost-effectiveness and assist decision
making.
Introduction
Antimicrobial resistance (AMR) is recognised as a global health security threat [1–6]. There
are concerns that the world may return to a pre-antimicrobial era where infectious diseases
could become untreatable [5] and many common medical procedures become much riskier to
undertake due to risk of incurable infection [1]. It is estimated that by 2050, ten million people
per year will die as a result of AMR [6] and annual global GDP could reduce by 1.1% relative
to a scenario with no AMR effect, with low and middle income countries (LMICs) expected to
be worst affected due to higher prevalence of infectious diseases and weaker health systems
[7]. Overuse and misuse of antimicrobial medicines are considered the lead driver of AMR so
efforts to reduce the over prescription of antibiotics is essential [8, 9].
In recent years, there has been improvement in diagnosis of malaria following the introduc-
tion of malaria Rapid Diagnostic Tests (RDTs) [10]. However, evidence suggests the improve-
ment in malaria diagnosis could be a driver for increased and unnecessary use of antibiotics
[11, 12]. Antibiotic prescription is often the default treatment decision for malaria-negative
febrile patients because symptoms for bacterial infection are difficult to distinguish from other
infections (e.g. viral, fungal, parasitic) [13]. In the majority of cases, the prescription is unnec-
essary as evidence suggests only a small proportion (10–15%) would have a bacterial infection
[14, 15].
In suspected bacterial infections, culture remains the gold standard for detection and treat-
ment [16]. This does not routinely happen in most malaria endemic countries because of the
absence of culturing facilities at the periphery of health systems where most malaria patients
are treated. Where testing is available, the time taken for samples to be processed is incompati-
ble with the pressure on the clinician to treat or the unaffordability of laboratory services to
patients [17]. Point-of-Care C-Reactive Protein (POCCRP) tests are a potential solution to
ascertain whether a patient has a bacterial infection and if an antibiotic is appropriate treat-
ment [18–24]. POCCRP could prove useful in LMICs for reducing unnecessary selection of
antibiotic resistance where laboratory services are limited and antibiotics are available over the
counter without prescription.
C-Reactive Protein (CRP) is a non-specific biomarker of inflammation, which gives an
indication of likely bacterial infection [21]. POCCRP tests are rapid tests that detect CRP con-
centration in the blood at a given concentration, providing a result within 15 minutes [22].
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Research to date on POCCRP has focused on high income countries and respiratory tract
infections (RTIs) [19, 20, 23, 25, 26]. There has been limited research in LMICs on febrile ill-
ness of uncertain cause [18, 22, 27]. POCCRP tests have been shown to be effective in reducing
unnecessary use of antibiotics in patients with RTIs [19, 25, 28, 29]. There is insufficient data
to indicate that POCCRP tests would reduce unnecessary antibiotic prescriptions in LMICs in
febrile patients who turn out not to need them [18, 21].
Economic analysis evidence indicates that POCCRP testing could be cost effective [20, 23,
25, 27]. In Norway and Sweden, it was estimated POCCRP testing had a cost per quality-
adjusted life year (QALY) gained of €9391, with a 70% probability of being cost-effective at a
willingness-to-pay (WTP) threshold of €30,000 per QALY gained [23]. In a LMIC setting, one
study in Vietnam found that introduction of POCCRP was unlikely to be cost-saving due to
high non-adherence rate to negative test results [27]. To our knowledge, there is no evidence
that compares the costs and outcomes, in an economic evaluation framework, of POCCRP in
a LMIC setting. Afghanistan is an example of a country of extreme poverty, endemic for vivax
and falciparum malaria, with a shortage of laboratory facilities, but is also a place where the
majority of febrile illness is not malarial but more likely to be bacterial or viral in origin [11,
14, 30]. It is in this type of epidemiological setting with moderate to low malaria risk where a
POCCRP test might prove of great service for diagnosis and treatment. The aim of this paper
was to determine the cost-effectiveness of POCCRP test compared to current clinical practice
for malaria-negative febrile patients in Afghanistan, using a pre-existing primary dataset on
costs of introducing malaria RDTs and secondary data sources on POCCRP tests.
Materials and methods
Study design
A cost-effectiveness analysis (CEA) framed in the evidence-based medicine PICO framework
[31]: the Population was febrile malaria negative cases in 22 primary health care facilities in
two provinces of Afghanistan [30]; the Intervention was a POCCRP test following a negative
malaria diagnosis; the Comparison group was “current clinical practice” after a febrile patient
is diagnosed as malaria-negative, where diagnosis is based on patient symptoms using treat-
ment guideline [32]; the Outcome was febrile malaria-negative patient correctly treated. A cor-
rectly treated case was defined as: 1) bacterial infection treated by an antibiotic; 2) other cause
of fever not treated by an antibiotic.
A decision tree model, developed in Microsoft1 Excel1 Version 2002, was used to con-
duct a CEA from two perspectives: public healthcare and societal (incorporating patient and
carer costs in addition to health sector costs). A further scenario analysis was conducted to
include estimated economic cost of AMR per prescription of antibiotics. The model time hori-
zon was 28-days post initial consultation, deemed sufficient to capture the duration of the visit
to the healthcare facility and subsequent costs for patients and carers. Beyond 28 days, it was
assumed that all costs and outcomes were independent of the testing pathway chosen. Dis-
counting of costs and outcomes was not required given the short time span.
Population
The population for the economic model cohort was taken from primary data collected during
an individual randomised trial (IRT) comparing effectiveness of malaria diagnostic interven-
tions in primary health clinics in Afghanistan [30]. The POCCRP CEA included a population
of 4,391 patients (mean age, 17.9 years). Data for the IRT were collected between 23 September
2009 and 22 September 2010 [30]. Inclusion criteria from the dataset was a patient diagnosed
as malaria-negative after being randomised to either the malaria RDT or clinical microscopy
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arms of the IRT. The IRT had a third arm which diagnosed by clinical symptoms but this arm
was not considered in the model given the extremely high false positive rates for suspected
malaria patients diagnosed by clinical signs and symptoms alone [11].
POCCRP test intervention and accuracy
It is important to note that the POCCRP test detects CRP concentration in the blood, not spe-
cifically a bacterial infection. A given concentration level of CRP can provide an indication of
bacterial infection but not all bacterial infection patients will exhibit increased CRP levels; sim-
ilarly, patients with other causes of infection will not always exhibit lower levels of CRP [21].
Thus, the CRP test can be seen as a clinical decision making tool, rather than a diagnostic test
for bacterial infection. Accordingly, the model accounts for: 1) the probability that a ‘bacterial
infection’ patient would have CRP concentration of 10 mg/L, and the probability of an ‘other
cause’ patient having a CRP concentration of less than 10 mg/L; and 2) the sensitivity and spec-
ificity of the POCCRP test to detect CRP concentration at 10 mg/L.
DTS233 POCCRP test was chosen for the study because of its 10mg/L threshold for a posi-
tive result and its simple visual interpretation [22]. 10 mg/L threshold was chosen due to the
remote setting of the study. By increasing the CRP threshold, it would decrease the number of
false positives but also decrease true positives. As there would be limited possibility for patients
to obtain emergency care it was advisable to accept a higher rate of false positives [22].
DTS233’s visual interpretation for positive, negative or invalid results is very simple compared
to other POCCRP tests (see Fig 1) [22].
Reference standards
Tests used for clinical decision making must be compared to a reference standard to determine
sensitivity and specificity [33]. In this study, Sensitivity and specificity of the POCCRP test to
Fig 1. DTS233 visual interpretation [22].
https://doi.org/10.1371/journal.pone.0258299.g001
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detect CRP is cited from a study in rural Laos, where a NycoCard Reader II (immunochemical
assay for the quantitative determination of CRP) was used as the reference standard to provide
information as to how sensitive and specific the POCCRP test is to detect CRP at 10mg/L does
not factor in sensitivity and specific of the NycoCard Reader [22]. At greater than or equal to
10 mg/L, NycoCard Reader II is estimated to have a sensitivity of 94.4% and specificity of
83.3% [34]. Sensitivity and specificity of the NycoCard Reader is not accounted for in the
study model.
Laboratory microbiological diagnosis was the reference standard used to assess the proba-
bility of a bacterial infection patient having CRP concentration of 10 mg/L or greater, and
probability of a non-bacterial infection patient having a CRP concentration of less than 10 mg/
L [21].
Outcome measure
The outcome measured was the number of febrile malaria-negative patients correctly treated.
A correctly treated case was defined as: 1) bacterial infection treated by an antibiotic; 2) other
cause of fever not treated by an antibiotic.
Model structure
A decision tree model was developed to compare two approaches to treating malaria-negative
febrile patients in Afghanistan. This model structure was chosen as the febrile condition has a
short, fixed timeline with no transition between disease states. Fig 2 shows the decision tree
with treatment pathways for the two study arms: Arm 1 –current clinical practice where treat-
ment was based on symptoms; and Arm 2 –POCCRP intervention where treatment was based
on the result of the POCCRP test.
The model started with a febrile patient who has been diagnosed as malaria-negative. The
cause of the fever could either be a bacterial infection or other cause. In arm 1, the patient
received a diagnosis and treatment based on symptoms. Whilst in arm 2, the patient received a
POCCRP test to guide the diagnosis. Treatment was given according to the test result, where a
CRP concentration of greater than or equal to 10mg/L indicated a bacterial infection, and a
CRP concentration of less than 10 mg/L indicated other cause. Arm 2 has a stage to factor in
probability that a patient will have a CRP concentration of greater than or equal to 10 mg/L
CRP, or less than 10mg/L CRP; this is important as not all bacterial infections will have a CRP
concentration of 10mg/L or above and not all non-bacterial infections will show a CRP con-
centration below 10 mg/L. For a bacterial infection diagnosis, an antibiotic prescription is rec-
ommended; for other cause of fever diagnosis, no antibiotic was prescribed.
Model parameters and sources
Probability parameters. The prevalence (proportion) of malaria negative patients with a
bacterial infection at a particular point in time, was taken from an unpublished study on causes
of undifferentiated fever in Afghanistan [14]. This source was chosen as there is a very limited
evidence base in non-malaria febrile patients across many countries [15, 37–40]. The probabil-
ity of being prescribed antibiotic under current clinical practice was derived from the primary
dataset for the study on introduction of malaria RDTs in Afghanistan by looking at the propor-
tion of malaria-negative patients that received antibiotics as treatment [30]. Data on CRP cut
off points (lower than or greater than CRP 10mg/L) are taken from a study in South East Asia
assessing the predictive value of CRP as an indicator for bacterial or non-bacterial infection
[21]. Data for sensitivity of POCCRP test for detection of CRP concentration at 10 mg/L and
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specificity of POCCRP test for non-detection of CRP concentration of less than 10 mg/L is
taken from a study on accuracy of commercially available CRP tests [22].
Cost parameters. The cost of a POCCRP test kit is taken from an estimate per unit cost,
allowing for import tariffs, shipment and other expenses, in a cost comparison study of intro-
duction of POCCRP in the management of acute respiratory infections in the Vietnamese pri-
mary healthcare setting [27]. Cost data for training to administer and interpret tests,
outpatient services delivery cost, dispensary costs, patient out of pocket expenditure, patient
and carer opportunity costs, and cost of a course of antibiotics were all taken from a primary
Fig 2. Decision tree. The square decision node indicates the decision point between the two arms; circular chance nodes show points where two alternative events for
a patients are possible [35]. Branches emanating from each chance node indicate possible events and the sum of their probabilities must equal 1; and triangular
terminal nodes are at the ends of pathways and represent the outcome of interest [36]. Recommended treatments are green and incorrect treatments are red. Pathways
are mutually exclusive sequences of events [35].
https://doi.org/10.1371/journal.pone.0258299.g002
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data set from the cost-effectiveness study of the introduction of malaria RDTs in Afghanistan
[41]. We have chosen this study to populate model cost parameters where possible because it
represents a sample of patients with fever that has been diagnosed as malaria-negative and is
the best available data in the Afghan setting. Economic cost of AMR to society per full course
of antibiotics is taken from a study in Thailand on the economic cost of antimicrobial resis-
tance per antibiotic consumed [42]. More detail on model parameters and sources can be
found in the table in S2 Appendix: model parameters and sources.
Primary data for the malaria RDT IRT [30] and CEA [41] in Afghanistan was provided by
respective lead authors (TL and KSH). Patient data was anonymised. Ethical approval for the
data collections has been granted by London School of Hygiene and Tropical Medicine and
The Afghan Institutional Review Board. The approvals allow data sharing and use of data for
other purposes. The malaria RDT IRT trial and associated CEA was registered at Clinincal-
Trials.gov (NCT00935688).
Table 1 shows inputs to build up the decision tree model and distributions assigned for the
probabilistic sensitivity analysis (PSA).
Where cost data is taken from a sample set, the standard deviation (SD) and sample size are
used to derive 95% confidence intervals. Where cost data is based on a single deterministic
value, SD is assumed to be 20% of deterministic value in the absence of a sample from which
to derive SD.
Costs were converted to 2019 USD. AFG prices are adjusted accounting for average infla-
tion over 10 years [43] and converted to USD at the exchange rate of 27 August 2019 [44]. The
economic cost of AMR data is based an estimate from Thailand [42]. This is adjusted for
Afghanistan using purchasing power parity (PPP) rates from April 2019 [45].
Analysis
Deterministic analysis. Using the decision tree model, the expected cost and outcome
between the two study arms were estimated. The incremental cost-effectiveness ratio (ICER)
was expressed as incremental cost per correctly treated patient, calculated by dividing the




C1 = POCCRP intervention cost
C0 = Current clinical practice cost
E1 = Number of correctly treated patients (POCCRP)
E0 = Number of correctly treated patients (current clinical practice)
Univariate sensitivity analysis. Univariate sensitivity analysis was undertaken on the sce-
nario analysis (societal including economic cost of AMR) to assess the impact of each parame-
ter on the ICER and to identify key drivers of the model. One variable was adjusted while all
other variables remained constant. Lower and upper bounds were set for each parameter
based on upper and lower 95% confidence intervals (CIs). If 95% CIs were not available,
parameters were varied by +/- 5%. The range in ICER for each variable between upper and
lower bounds was presented in a tornado diagram.
Probabilistic sensitivity analysis. A probabilistic sensitivity analysis (PSA) was under-
taken to characterise parameter uncertainty and test the robustness of the ICER of the model
results to variation in data inputs. Monte Carlo simulation was undertaken by running 1,000
simulations, randomly selecting values from each parameter’s distribution simultaneously for
each simulation. As all chance nodes only have two branches (binary), beta distributions were
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assigned to probability parameters; alpha and beta values were derived from counts of events
of interest as a proportion of total sample [35]. Gamma distributions were assigned to all cost
parameters, accounting for the skewed nature of cost data bounded by 0, derived from the
Table 1. Model inputs.
Parameter Parameter Description Population (patients)
Pop Population 4391
Cost Parameter Parameter Description Mean ($)� SD
($)
95% CI Distribution (α, β) + Source
cTEST Cost of the POCCRP test kit 1.00 0.20 0.61–
1.39
Gamma (25, 0.04) [27]
cTRAIN Training to administer and interpret test 0.03 0.01 0.02–
0.04
Gamma (25, 0.001) [41]





cDISP Dispensary cost at healthcare facility 1.33 0.10 1.29–
1.38
Gamma (2.31, 0.58) [41]





cPLTapp Opportunity cost of patient’s time—appropriate treatment 3.20 4.47 2.89–
4.74
Gamma (0.51, 0.07) [41]





cOPEnot Patient out of pocket expenditure—inappropriate treatment 5.61 17.16 4.32–
6.91
Gamma (14.77, 0.38) [41]
cPLTnot Opportunity cost of patient’s time—inappropriate treatment 4.15 4.90 3.78–
4.52
Gamma (99.01, 0.04) [41]
cCLTnot Opportunity cost of carer’s—inappropriate treatment 1.85 2.42 1.67–
2.03
Gamma (80.67, 0.02) [41]
cANTI Cost per full course of antibiotics 0.12 0.02 0.11–
0.12
Gamma (25, 0.005) [41]
cAMR Cost of AMR to society per full course of antibiotics 4.39 0.88 2.67–
6.11
Gamma (25, 0.18) [42]
Probability
Parameter
Parameter Description Probability� 95% CI Distribution (α, β) + Source
pBac Prevalence of bacterial infection among malaria-negative patients 0.10 0.09–0.10 Beta (15, 142) [14]
pDIAGanti Probability of being prescribed antibiotic under current clinical practice 0.56 0.56–0. 56 Beta (2479, 1912) [30]
pSENSpoccrp Sensitivity of POCCRP test for detection of CRP concentration at 10 mg/L 0.95 0.87–0.97 Beta (86, 5) [22]
pSPECpoccrp Specificity of POCCRP test for non-detection of CRP concentration of less
than 10 mg/L
0.98 0.92–1.00 Beta (75, 2) [22]
pBACcrp>10 Probability of bacterial infection patient having CRP concentration of 10 mg/
L
0.95 0.92–0.97 Beta (404, 21) [21]
pOTHcrp<10 Probability of non-bacterial infection patient having CRP concentration of
less than 10 mg/L
0.49 0.46–0.53 Beta (464, 483) [21]
� Value used for the deterministic model.
+ Distribution for PSA.
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mean and standard error of the sampling distribution [35]. The simulations for the two differ-
ent cost perspectives (health care delivery and societal) and scenario analysis (societal includ-
ing economic cost of AMR) are presented as cost-effectiveness planes [35]. Expected outcomes
for the POCCRP intervention compared to the current clinical practice were expressed as
monetary net benefits for a specified value of WTP with the option with the highest net benefit
being considered most cost-effective. The model was run for values of WTP from $0 to $200
per correctly treated patient at intervals of $0.50 for all cost perspectives. The output for each
trial setting was presented graphically as cost-effectiveness acceptability curves [35].
Scenario analysis
A scenario analysis was undertaken to attempt to incorporate the economic cost of AMR per
prescription of antibiotics. The scenario analysis builds on the societal perspective, incorporat-
ing an additional cost parameter (economic cost of AMR per prescription). The economic cost
of AMR included the additional cost of treating patients with resistant infections and the indi-
rect productivity losses due to excess mortality attributable to resistant infections [42]. The
estimate for this parameter was for a broad-spectrum penicillin (BSP), assumed to drive resis-
tance in 5 pathogens in Thailand. A BSP was chosen as the most likely antibiotic to be used as
first line treatment in Afghanistan.
Results
Deterministic ICER
Table 2 illustrates the results of the deterministic analysis. From a healthcare delivery perspec-
tive, the base case deterministic ICER is $14.33 per additional correctly treated febrile malaria-
negative patient. From a broader, societal perspective, the ICER falls to $11.22. A scenario
analysis including the economic cost of AMR reduces the ICER further to $9.60.
Population for the study is 4,391 patients. Compared to current clinical practice, there was
an incremental positive effect of 421 patients treated correctly (9.6% of population) with the
POCCRP intervention. Of the population (4,391), 45% (1,966) patients received the correct
treatment under current clinical practice; while under the POCCRP intervention, 54% (2,387)
received correct treatment. The introduction of the POCCRP intervention resulted in a 6%
overall reduction in antibiotic prescriptions (137 / 2,479) across the study population. More
significantly, there was a 12% reduction (279 / 2,242) in incorrect antibiotic prescriptions
when comparing the POCCRP intervention to current clinical practice.
The decision tree model with all costs and probabilities assigned can be seen in S3 Appen-
dix: populated decision tree.
Sensitivity analysis
Univariate. Univariate sensitivity analysis shows there were 12 variables that had an effect
greater than $0.50 on the deterministic ICER when varied between their upper and lower
bounds. Tornado plot in Fig 3 illustrates the range effect of the 12 variables.
Table 2. Deterministic ICERs for healthcare delivery, societal and scenario analysis.
Perspective Current clinical practice















1,653 7,689 6,036 1,966 2,387 421 14.33
Societal 46,487 51,212 4,725 11.22
Scenario
analysis
57,371 61,413 4,042 9.60
https://doi.org/10.1371/journal.pone.0258299.t002
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The probability of being treated with an antibiotic in current clinical practice was the
parameter that had the greatest impact on ICER (range $20.82). Cost of the POCCRP test kit
was the parameter that has the second greatest impact on ICER (range $10.91). Specificity of
bacterial infection being detected at 10mg/L (i.e. the probability that non-bacterial infection
does not have CRP concentration of 10 mg/L) followed with a range of effect of $10.71. The
specificity and sensitivity of the POCCRP test kit followed as the fourth and fifth in terms of
range effect on ICER (respective ranges: $8.06 and $7.19).
Table 3 shows the lower and upper bounds used to vary parameters for the univariate sensi-
tivity analysis.
Probabilistic sensitivity analysis. Of the population (4,391), the probabilistic model indi-
cated that 1,966 (45%) patients received the correct treatment under current clinical practice;
while with the POCCRP intervention, the model indicated that 2,396 (55%) received correct
treatment. Fig 4 is the cost-effectiveness for results from the PSA for the healthcare delivery
Fig 3. Univariate sensitivity tornado diagram–scenario analysis: Societal perspective (including cost of AMR).
https://doi.org/10.1371/journal.pone.0258299.g003
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perspective. The diagram shows the uncertainty in incremental effect on the x-axis and incre-
mental cost on the y-axis. The mean incremental effect is 9.8%, showing that the intervention
is likely to be more effective than current clinical practice. On average, the POCCRP interven-
tion is more expensive with an incremental cost of $1.43.
For societal perspective, the mean incremental effect was unaffected as the societal cost
does not impact upon the measure of outcome. For both the societal perspective and the sce-
nario analysis including the economic cost of AMR, the POCCRP intervention was on average
more expensive. In the societal perspective, average incremental cost was $1.13; when includ-
ing cost of AMR in the scenario analysis, average incremental cost fell to $0.96. Figs 5 and 6
are cost-effectiveness planes with results from the PSA of the societal cost perspective and sce-
nario analysis including economic cost of AMR. There was greater uncertainty with regard
cost, compared to the healthcare delivery cost perspective. Data points were both positive and
negative in terms of cost, thus in some simulations the intervention was dominant over current
clinical practice (i.e. it is more effective and less costly). For the societal cost perspective 6% of
simulations (60/1000) estimated POCCRP intervention to be less costly compared to the














Probability of being prescribed antibiotic
under current clinical practice
0.56 0.51 0.61 + / - 5% $25.31 $4.49 $20.82
Cost of the POCCRP test kit $1.00 $0.61 $1.39 95% CI $4.14 $15.05 $10.91
Specificity of non-bacterial infection patient
having CRP concentration of less than 10 mg/
L
0.49 0.46 0.53 95% CI $15.80 $5.09 $10.71
Specificity of POCCRP test for non-detection
of CRP concentration of less than 10 mg/L
0.98 0.92 1 95% CI $16.20 $8.13 $8.06
Sensitivity of POCCRP test for detection of
CRP concentration at 10 mg/L
0.95 0.87 0.98 95% CI $4.97 $12.16 $7.19
Patient out of pocket expenditure—
inappropriate treatment
$5.61 $4.32 $6.91 95% CI $10.89 $8.57 $2.32
Patient out of pocket expenditure—
appropriate treatment
$3.82 $2.89 $4.74 95% CI $8.67 $9.88 $1.21
Cost of AMR to society per full course of
antibiotics
$4.39 $2.67 $6.11 95% CI $10.16 $9.04 $1.12
Prevalence of bacterial infection among
malaria negative patients
0.10 0.05 0.15 + / - 5% $9.90 $8.80 $1.10
Overhead cost of running the pharmacy/
dispensary at the healthcare facilities
1.33 1.29 1.38 95% CI $9.13 $10.06 $0.93
Opportunity cost of patient’s time—
appropriate treatment
$3.08 $2.70 $3.47 95% CI $9.21 $9.98 $0.77
Opportunity cost of patient’s time—
inappropriate treatment
$4.15 $3.78 $4.52 95% CI $9.97 $9.23 $0.74
Opportunity cost of carer’s time—appropriate
treatment
$1.44 $1.24 $1.65 95% CI $9.39 $9.80 $0.41
Sensitivity of bacterial infection patient having
CRP concentration of 10 mg/L
0.95 0.92 0.97 95% CI $9.84 $9.44 $0.39
Training to administer and interpret the test $0.03 $0.02 $0.04 95% CI $9.43 $9.76 $0.33
Opportunity cost of carer’s time—
inappropriate treatment
$1.85 $1.67 $2.03 95% CI $9.13 $9.41 $0.28
Cost per full course of antibiotics in
Afghanistan
$0.12 $0.11 $0.12 95% CI $9.60 $9.60 $0.00
Outpatient services delivery cost $0.28 $0.25 $0.31 95% CI $9.60 $9.60 $0.00
https://doi.org/10.1371/journal.pone.0258299.t003
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current clinical practice. For the scenario analysis (societal perspective including economic
cost of AMR), this rose to 13% of simulations (130/1000) estimating POCCRP intervention to
be less costly compared to current clinical practice.
The uncertainty in the cost-effectiveness planes was summarised in the cost-effectiveness
acceptability curves (Fig 7), showing the probability that introduction of the POCCRP inter-
vention is cost-effective according to different levels of WTP for an appropriately treated
patient for each of the cost perspectives. For healthcare delivery perspective, if WTP for addi-
tional correctly treated patient is zero, there was a 0% probability that the intervention can be
considered cost effective. However, for societal perspective and the scenario analysis including
cost of AMR, the model shows 6% and 13% respective probabilities that the intervention
would be considered good value at WTP of zero. For healthcare delivery perspective, if we
increase WTP to $12.50, the probability of cost effectiveness increased to 50%. For the societal
cost perspectives, probability of cost effectiveness remains higher at 61% and 66% respectively.
For healthcare delivery cost, WTP of $30.50 showed a 90% probability that the intervention
was cost effective. For societal cost perspective and the scenario analysis including cost of
AMR, 90% probability of cost effectiveness was not reached until WTP of $27.50 and $26.00
respectively.
Discussion
The cost-effectiveness analysis of POCCRP test for malaria-negative febrile patients shows that
replacing current clinical practice by POCCRP intervention is likely to be more effective com-
pared to current clinical practice, but also likely to be more costly. Compared to current clini-
cal practice, the introduction of POCCRP testing is likely to be associated with a reduction of
incorrect antibiotic prescriptions among malaria-negative febrile patients.
Fig 4. Probabilistic sensitivity analysis (health sector perspective): Scatter plot of incremental health sector cost and incremental effect
resulting from replacing current clinical practice by POCCRP testing.
https://doi.org/10.1371/journal.pone.0258299.g004
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Health service willingness to pay data is not available for correct treatment of malaria-nega-
tive febrile patients. The only comparable study that estimates health service willingness to pay
(WTP) was conducted in the USA, with a threshold of $43 per antibiotic prescription safely
avoided [46]. While the measure of outcome for the study was different, a reduction in unnec-
essary antibiotic prescriptions of 279 was observed at incremental costs for the intervention of
$6,036 (healthcare perspective), $4,725 (societal perspective), and $4,042 (scenario analysis).
This equates to a cost per unnecessary antibiotic prescription avoided of $21.63, $16.93 and
$14.49, respectively. While this comparison is from a high-income country and is only from
one study, it provides positive indication the POCCRP intervention could be cost-effective
and that further research is warranted. WTP for interventions to reduce unnecessary antibiotic
use are further complicated because when considering WTP, there are no immediate health
benefits to the patient–if an antibiotic is given unnecessarily, it will have little effect on treat-
ment outcomes compared to no antibiotic given in the first place. Thus, a patient would only
likely be willing to pay for the intervention if it cost less than the treatment. So, policy makers
(donors and governments) must make a decision to incur costs now to off-set future health
impacts. Given the global health security threat of AMR, it is possible that bilateral or multilat-
eral donors would consider funding interventions to reduce unnecessary use of antibiotics.
Research is required into WTP for correctly treated malaria-negative febrile patients to be able
to say with any certainty that the intervention would be cost effective.
There is debate as to what CRP concentration should be used to determine if a bacterial
infection is likely and an antibiotic required [18, 21, 47]. 10 mg/L is a relatively low CRP con-
centration threshold to consider prescription of an antibiotic as compared to what is used in
Fig 5. Probabilistic sensitivity analysis (societal perspective): Scatter plot of incremental health sector cost and incremental effect resulting from
replacing current clinical practice by POCCRP testing.
https://doi.org/10.1371/journal.pone.0258299.g005
PLOS ONE Cost-effectiveness of POCCRP to improve antibiotic prescription in malaria-negative patients in Afghanistan
PLOS ONE | https://doi.org/10.1371/journal.pone.0258299 November 8, 2021 13 / 20
high-income countries. For example in the United Kingdom, National Institute of Health and
CARE Excellence (NICE) advises a threshold of 20mg/L [47]. A lower threshold means there is
less likelihood of missing bacterial infections and in settings where there is little recourse for
emergency care this could be more appropriate. However, it also means that many more non-
bacterial infections are incorrectly diagnosed as bacterial infections. At a 20 mg/L threshold,
the sensitivity of detecting bacterial infections decreases to 86% compared to 95% at 10 mg/L,
and the specificity increases to 67% compared to 49% at 10 mg/L [21]. CRP concentration
threshold to consider prescription of an antibiotic would be an important factor for introduc-
tion of POCCRP and different thresholds could be tested alongside each other in any future
studies.
There are POCCRP tests that allow for interpretation of CRP concentration, indicating
bands of strength of concentration, such as the WD-23 and bioNexia CRPplus [26]. These
could be advantageous as they would allow a more nuanced interpretation by the healthcare
worker of the test, which they could then combine with patient symptoms to determine if an
antibiotic is required. Further research should consider different POCCRP tests, looking at dif-
ferences in functionality and accuracy, but also taking into account that increased complexity
to interpret results could adversely affect overall effectiveness.
Economic cost of AMR per prescription of antibiotics is an important element to any study
looking at cost-effectiveness of interventions to reduce unnecessary use of antibiotics. In the
model, we see ICER reduces by $1.62 between societal cost perspective ($11.22) and the sce-
nario analysis where economic cost of AMR is included ($9.60). The economic cost of AMR
Fig 6. Probabilistic sensitivity analysis (scenario analysis—societal perspective including economic cost of AMR): Scatter plot of incremental health
sector cost and incremental effect resulting from replacing current clinical practice by POCCRP testing.
https://doi.org/10.1371/journal.pone.0258299.g006
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Fig 7. Cost-effectiveness acceptability curves.
https://doi.org/10.1371/journal.pone.0258299.g007
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data used in the model is taken from one study based in Thailand [42] as there is limited
research that estimates cost of AMR by antibiotic prescription. The estimate used for this
parameter in the scenario analysis should be considered conservative as the source study is
“narrowly defined as the incremental cost of treating patients with resistant infections as com-
pared with sensitive ones, and the indirect productivity losses due to excess mortality attribut-
able to resistant infections” and the source considers cost of AMR for five pathogens only [42].
Further research is required to understand economic costs of AMR resulting from a prescrip-
tion of antibiotics so that this significant cost can be considered for interventions seeking to
reduce unnecessary use of antibiotics.
A further limitation of our modelling is that the time horizon is short (28 days). Whilst this
is sufficient to capture the endpoint of interest for the CEA, we acknowledge that it does not
sufficiently capture all the long-term benefits of reduced AMR, where quality of life gains and
mortality reduction may be realised. To achieve a robust estimate of the longer-term cost-
effectiveness would require a highly complex decision analysis model, over a lifetime horizon,
potentially restructured as a cost-utility analysis reporting QALY gains or DALYs averted.
Whilst it was not possible to achieve this within the scope of the current work, this is a promis-
ing area for future research.
While the study indicates that POCCRP intervention would likely be more effective com-
pared to current clinical practice in Afghanistan, there is limited scope to generalise the results
to other settings. The reason for this is that there is substantial heterogeneity in clinical prac-
tice, health system organisation, and unit costs of treatments across different settings. Further,
differing local epidemiological factors would impact upon cost-effectiveness of the interven-
tion (e.g. prevalence of bacterial infections in non-malaria febrile patients). Given positive
indications of the effectiveness of the intervention, further research is warranted in other
malaria endemic countries where POCCRP could contribute to reducing inappropriate pre-
scriptions of antibiotics.
The CEA has some important limitations. Household cost parameters accounted for a sig-
nificant amount of cost (84% in the societal cost perspective). Household data used included
malaria-positive and malaria-negative patients from the malaria RDT CEA study [41], as cost
data between the two could not be disaggregated from the primary dataset. Further, the dataset
had high variation in costs throughout the sample (observed by relatively high standard devia-
tions for these parameters). The model could be strengthened by more specific research into
patient and carer costs for malaria-negative patients only. Aetiology of non-malarial fever is an
area where there is limited data [15, 37–40] but this parameter is very important to understand
the effectiveness of POCCRP to reduce unnecessary antibiotic prescriptions. For the study,
data from Afghanistan was provided by researchers of an unpublished study [14]. The model
assumed that POCCRP test results will be adhered to in all cases by both healthcare worker
and patient but evidence from use of introduction of RDTs suggests this is unrealistic, with
non-adherence to negative tests being as high as 61% [27]. Future research into POCCRP test
cost-effectiveness should measure and account for non-adherence to negative test results.
This study builds on initial work in the area of POCCRP and is the first CEA to review
POCCRP to reduce inappropriate use of antibiotics in an LMIC. The study benefits from
using primary data from costs (healthcare and societal) for introduction of malaria RDTs in
Afghanistan.
Conclusion
The introduction of POCCRP tests could be effective to increase number of correctly treated
malaria-negative patients in Afghanistan and reduce unnecessary use of antibiotics compared
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to current clinical practice. Whether it can ultimately be considered good value for money is
dependent on WTP of policy makers and other possible funders. This study is based on a com-
bination of trial data for introduction of malaria RDTs and secondary sources on POCCRP
accuracy. To establish whether there is a place for POCCRP testing in clinical guidelines in
LMICs, primary data in a trial setting would be required. A trial would need to assess clinical,
microbiological and economic outcomes, as well as WTP of policy makers and donors. The
results of the study suggest that further research is warranted into the cost effectiveness of
POCCRP tests in malaria-negative patients to avoid unnecessary prescription of antibiotics in
Afghanistan. Research could also be expanded to other malaria endemic countries.
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